About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Shareholder Information Analyst Coverage Corporate Governance AIM Rule 26 Advisers Annual General Meeting Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 08 Feb 2019 Summit Therapeutics to Present at the BIO CEO & Investor Conference Press Releases / 10 Jan 2019 Completion of $25 million Subscription Press Releases / 04 Jan 2019 Result of General Meeting Press Releases / 17 Dec 2018 Proposed Subscription to Raise $25.0 million and Notice of General Meeting Press Releases / 17 Dec 2018 Summit Therapeutics Announces Departure of Chief Financial Officer Press Releases / 11 Dec 2018 Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress Press Releases / 12 Nov 2018 Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Press Releases / 01 Nov 2018 Summit Recognises C. difficile Awareness Month Press Releases / 10 Oct 2018 Summit Therapeutics to Participate in Upcoming Investor Events Press Releases / 03 Oct 2018 Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Press Releases / 26 Sep 2018 Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018 Press Releases / 20 Sep 2018 Financial Results for Second Quarter Ended 31 July 2018 << 1 2 3 … 24 25 >>
Press Releases / 08 Feb 2019 Summit Therapeutics to Present at the BIO CEO & Investor Conference Press Releases / 10 Jan 2019 Completion of $25 million Subscription Press Releases / 04 Jan 2019 Result of General Meeting Press Releases / 17 Dec 2018 Proposed Subscription to Raise $25.0 million and Notice of General Meeting Press Releases / 17 Dec 2018 Summit Therapeutics Announces Departure of Chief Financial Officer Press Releases / 11 Dec 2018 Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress Press Releases / 12 Nov 2018 Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Press Releases / 01 Nov 2018 Summit Recognises C. difficile Awareness Month Press Releases / 10 Oct 2018 Summit Therapeutics to Participate in Upcoming Investor Events Press Releases / 03 Oct 2018 Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Press Releases / 26 Sep 2018 Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018 Press Releases / 20 Sep 2018 Financial Results for Second Quarter Ended 31 July 2018
Press Releases / 17 Dec 2018 Proposed Subscription to Raise $25.0 million and Notice of General Meeting
Press Releases / 11 Dec 2018 Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress
Press Releases / 12 Nov 2018 Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
Press Releases / 03 Oct 2018 Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
Press Releases / 26 Sep 2018 Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
